CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 201–300 of 1,000
Hallow, K. M., Greasley, P. J., Helmlinger, G., Chu, L., Heerspink, H. J., & Boulton, D. W. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00202.2018 · Cited by 68
Lauritsen, K. M., Nielsen, B. R. R., Tolbod, L. P., Johannsen, M., Hansen, J., Hansen, T. K., Wiggers, H., Møller, N., Gormsen, L. C., & Søndergaard, E. (2020) · Diabetes · doi:10.2337/db20-0921 · Cited by 70
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa, B. C., Kibbey, R. G., & Inzucchi, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05815-1 · Cited by 76
Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease
Martinez-Moreno, J. M., Fontecha‐Barriuso, M., Martín‐Sánchez, D., Guerrero‐Mauvecin, J., Gomá-Garcés, E., Fernández‐Fernández, B., Carriazo, S. M., Sánchez-Niño, M. D., Ramos, A. M., Ruiz‐Ortega, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114113 · Cited by 71
Myocardial Metabolism in Heart Failure
Ng, S. M., Neubauer, S., & Rider, O. J. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00589-y · Cited by 77
Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock
Hansen, K. B., Christensen, K. H., Gopalasingam, N., Nielsen, R. R., Eiskjær, H., Møller, N., Birkelund, T., Christensen, S., & Wiggers, H. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.05.029 · Cited by 69
SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
Bell, R. M., & Yellon, D. M. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30314-5 · Cited by 70
Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy
Carpentier, A. C. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.029 · Cited by 71
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors
Thomson, S. C., & Vallon, V. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.027 · Cited by 74
Increased Glucose Availability Attenuates Myocardial Ketone Body Utilization
Brahma, M. K., Ha, C., Pepin, M. E., Mia, S., Sun, Z., Chatham, J. C., Habegger, K. M., Abel, E. D., Paterson, A. J., Young, M. E., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013039 · Cited by 66
Packer, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016270 · Cited by 72
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
Mulder, S., Heerspink, H. J. L., Darshi, M., Kim, J. J., Laverman, G. D., Sharma, K., & Pena, M. J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13823 · Cited by 65
Scheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.008 · Cited by 60
Epicardial fat links obesity to cardiovascular diseases
Iacobellis, G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.04.006 · Cited by 72
Goncalves, E., & Bell, D. S. H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0420-6 · Cited by 61
Abdurrachim, D., Teo, X. Q., Woo, C. C., Chan, W. X., Lalic, J., Lam, C. S. P., & Lee, P. T. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13536 · Cited by 68
Metabolism of the failing heart and the impact of SGLT2 inhibitors
García‐Ropero, Á., Santos‐Gallego, C. G., Zafar, M. U., & Badimón, J. J. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1588886 · Cited by 67
“Therefore, it appears conceivable that the overall physiological impact of KB follows an inverted U-shaped curve, whereby mild and intermittent elevations of KB are beneficial (as under SLGT2 inhibitor therapy), while very low or high continuous levels might be harmful [22].”
BackgroundInfluentialZhang, D.-P., Xu, L., Wang, L.-F., Wang, H.-J., & Jiang, F. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-0987-x · Cited by 64
Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond
Yu, W., Xie, D., Yamamoto, T., Koyama, H., & Cheng, J. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09787-4 · Cited by 70
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Li, J., Yu, Y., Sun, Y., Yu, B., Tan, X. W., Wang, B., Lu, Y., & Wang, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02019-8 · Cited by 74
“SGLT2 inhibitors were believed to have extra beneficial metabolic effects beyond glycemic control, [10, 11] which might play an important role in improving cardiovascular and renal outcomes.”
BackgroundEmpagliflozin improves left ventricular diastolic function of db/db mice
Moellmann, J., Klinkhammer, B. M., Droste, P., Kappel, B. A., Haj‐Yehia, E., Maxeiner, S., Artati, A., Adamski, J., Boor, P., Schütt, K. S., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165807 · Cited by 69
Oldgren, J., Laurila, S., Åkerblom, A., Latva‐Rasku, A., Rebelos, E., Isackson, H., Saarenhovi, M., Eriksson, O., Heurling, K., Johansson, E., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14363 · Cited by 68
Self-citationSomagutta, M. K. R., Agadi, K., Hange, N., Jain, M. S., Batti, E., Emuze, B. O., Amos-Arowoshegbe, E. O., Popescu, S., Hanan, S., Kumar, V. R., et al. (2021) · Cureus · doi:10.7759/cureus.13665 · Cited by 80
Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Zhang, R., Xie, Q., Lu, X., Fan, R., & Tong, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01325-9 · Cited by 65
“Ferannini et al. postulated that the glycosuria induced by empagliflozin results in a reduced insulin-to-glucagon ratio, thereby promoting increased hepatic FFA oxidation, consequently leading to an upsurge in circulating BHB levels [82].”
BackgroundSGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
Santos‐Gallego, C. G., Mayr, M., & Badimón, J. J. (2022) · Circulation · doi:10.1161/circulationaha.122.060805 · Cited by 66
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
SGLT2 Inhibitors: The Sweet Success for Kidneys
Dharia, A., Khan, A. A., Sridhar, V. S., & Cherney, D. Z. I. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-102135 · Cited by 69
Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors
Wójcik, C., & Warden, B. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1219-4 · Cited by 71
Theofilis, P., Antonopoulos, A. S., Katsimichas, T., Oikonomou, E. K., Siasos, G., Aggeli, C., Tsioufis, K. P., & Tousoulis, D. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106243 · Cited by 63
de Boer, R. A., Núñez, J. E., Kozlovski, P., Wang, Y., Proot, P., & Keefe, D. L. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14248 · Cited by 63
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
Pietschner, R., Kolwelter, J., Bosch, A., Striepe, K., Jung, S., Kannenkeril, D., Ott, C., Schiffer, M., Achenbach, S. S., & Schmieder, R. E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01410-7 · Cited by 64
Sulaj, A., Kopf, S., von Rauchhaupt, E., Kliemank, E., Brune, M., Κender, Ζ., Bartl, H., Cortizo, F. G., Klepac, K., Han, Z., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac197 · Cited by 66
Nishitani, S., Fukuhara, A., Shin, J., Okuno, Y., Otsuki, M., & Shimomura, I. (2018) · Scientific Reports · doi:10.1038/s41598-018-27181-y · Cited by 62
Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics
Ferrannini, E., Murthy, A. C., Lee, Y.-H., Muscelli, E., Weiss, S., Ostroff, R. M., Sattar, N., Williams, S. A., & Ganz, P. (2020) · Diabetes Care · doi:10.2337/dc20-0456 · Cited by 61
Self-citationSternlicht, H., & Bakris, G. L. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0920-4 · Cited by 60
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 59
Thirunavukarasu, S., Jex, N., Chowdhary, A., Hassan, I. U., Straw, S., Craven, T. P., Gorecka, M. M., Broadbent, D. A., Swoboda, P., Witte, K. K., et al. (2021) · Diabetes · doi:10.2337/db21-0270 · Cited by 64
Goedeke, L., Ma, Y., Gaspar, R. C., Nasiri, A. R., Lee, J., Zhang, D., Galsgaard, K. D., Hu, X., Zhang, J., Guerrera, N. M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176708 · Cited by 67
“In light of these studies, ketones have been hypothesized to be a “thrifty-fuel” (9), with increases in ketone availability (either directly by ketone infusion or indirectly through SGLT2 inhibition) being demonstrated to reduce Previous studies highlight the potential for sodium-glucose…”
Kim, Y., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K., & Kim, H. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13297 · Cited by 57
Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
Nishinarita, R., Niwano, S., Niwano, H., Nakamura, H. K., Saito, D., Sato, T., Matsuura, G., Arakawa, Y., Kobayashi, S., Shirakawa, Y., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.119.017483 · Cited by 63
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients
Starčević, J. N., Janić, M., & Šabović, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051197 · Cited by 66
Iacobellis, G., & Baroni, M. G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 56
Mitochondria as Therapeutic Targets in Heart Failure
Schwemmlein, J., Maack, C., & Bertero, E. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00539-0 · Cited by 60
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 66
Kwon, O., Myong, J., Lee, Y., Choi, Y.-J., Yi, J. E., Seo, S. M., Jang, S.-W., Kim, P. J., & Lee, J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027824 · Cited by 60
Stoicescu, L., Crișan, D., Morgovan, C., Avram, L., & Ghibu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020794 · Cited by 65
Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 57
Molecular Mechanisms Underlying the Bioactive Properties of a Ketogenic Diet
Murakami, M., & Tognini, P. (2022) · Nutrients · doi:10.3390/nu14040782 · Cited by 59
SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
Rastogi, A., & Bhansali, A. K. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0320-1 · Cited by 57
Butt, J. H., Docherty, K. F., Petrie, M. C., Schou, M., Kosiborod, M., O’Meara, E., Katova, T., Ljungman, C. E. A., Díez, M., Ogunniyi, M. O., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.0379 · Cited by 61
Mascolo, A., Scavone, C., Scisciola, L., Chiodini, P., Capuano, A., & Paolisso, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105836 · Cited by 60
Ketone Bodies and Cardiovascular Disease: An Alternate Fuel Source to the Rescue
Manolis, A. S., Manolis, T. A., & Manolis, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043534 · Cited by 59
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Kolesnik, E., Scherr, D., Rohrer, U., Benedikt, M., Manninger, M., Sourij, H., & von Lewinski, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031678 · Cited by 60
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Ali, A., Bain, S. C., Hicks, D., Jones, P. N., Patel, D., Evans, M., Fernando, K., James, J., Milne, N., Viljoen, A., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0657-8 · Cited by 62
Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Giaccari, A., Solini, A., Frontoni, S., & Prato, S. D. (2021) · Diabetes Care · doi:10.2337/dc20-1964 · Cited by 55
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Avogaro, A., Fadini, G. P., Sesti, G., Bonora, E., & Prato, S. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0431-4 · Cited by 55
Li, X., Preckel, B., Hermanides, J., Hollmann, M. W., Zuurbier, C. J., & Weber, N. C. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15850 · Cited by 55
Bajaj, H. S., Brown, R. E., Bhullar, L., Sohi, N., Kalra, S., & Aronson, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.001 · Cited by 50
Sheu, W. H., Chan, S. P., Matawaran, B. J., Deerochanawong, C., Mithal, A., Chan, J. C. N., Suastika, K., Khoo, C. M., Nguyen, H. M., Ji, L., et al. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0208 · Cited by 56
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Jensen, J., Omar, M., Kistorp, C., Poulsen, M. K., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Fosbøl, E. L., Bruun, N. E., et al. (2019) · Trials · doi:10.1186/s13063-019-3474-5 · Cited by 55
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Salah, H. M., Verma, S., Santos‐Gallego, C. G., Bhatt, A. S., Vaduganathan, M., Khan, M. S., Lópes, R. D., Alaref, S. J., McGuire, D. K., & Fudim, M. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10220-5 · Cited by 54
Mechanisms linking empagliflozin to cardiovascular and renal protection
Filardi, P. P., Avogaro, A., Bonora, E., Colivicchi, F., Fioretto, P., Maggioni, A. P., Sesti, G., & Ferrannini, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.089 · Cited by 55
Self-citationKim, Y., Han, S. J., Kim, D. J., Lee, K. W., & Kim, H. J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0737-5 · Cited by 53
Chin, K. L., Ofori‐Asenso, R., Hopper, I., von Lueder, T. G., Reid, C. M., Zoungas, S., Wang, B. H., & Liew, D. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy295 · Cited by 56
CHILTON, R. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13854 · Cited by 54
“It is believed that mild, persistent hyperketonaemia, which occurs during treatment with SGLT-2is, leads to cardiac uptake and oxidization of the ketone body β-hydroxybutyrate in preference to fatty acids.(63) SGLT-2i therapy may, therefore, promote metabolic changes, increasing the hepatic synthesis of ketones, inclu…”
BackgroundBerra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 48
Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., Schou, M., Kosiborod, M., Langkilde, A. M., Martínez, F. A., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2124 · Cited by 55
Aguilar-Gallardo, J. S., Correa, A. A., & Contreras, J. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab056 · Cited by 54
Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
Dabravolski, S. A., Zhuravlev, A. D., Kartuesov, A. G., Borisov, E. E., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105371 · Cited by 56
Ritsinger, V., Nyström, T., Saleh, N., Lagerqvist, B., & Norhammar, A. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319901063 · Cited by 52
Adaptive Cardiac Metabolism Under Chronic Hypoxia: Mechanism and Clinical Implications
Su, Z., Liu, Y., & Zhang, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.625524 · Cited by 53
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Chen, J., Jiang, C., Guo, M., Zeng, Y., Jiang, Z., Zhang, D., Tu, M., Tan, X., Yan, P., Xu, X.-M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02042-9 · Cited by 56
“…alter substrate utilization and cellular signaling though increased lipolysis in adipose tissue with subsequent generation of ketone bodies [54]; reduc the leakage of Ca 2 + from sarcoplasmic reticulum (SR) thereby enhancing Ca 2 + transient amplitude in cardiomyocytes and improving…”
BackgroundKaneto, H., Obata, A., Kimura, T., Shimoda, M., Kinoshita, T., Matsuoka, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063062 · Cited by 50
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease
Mima, A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01735-5 · Cited by 54
Renal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 54
Giugliano, D., Longo, M., Scappaticcio, L., Caruso, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01213-w · Cited by 48
Sohn, M., Jung, H., Lee, W. S., Kim, T. H., & Lim, S. K. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0370 · Cited by 56
“Transient increases in the levels of free fatty acids that can be mobilized for oxidation have been shown after the administration of an SGLT2 inhibitor [32].”
Rizo‐Roca, D., Henderson, J. D., & Zierath, J. R. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20090 · Cited by 54
“The benefit is thought to arise from enhanced fatty acid oxidation in cardiac cells [158].”
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
McGovern, A. P., Feher, M. D., Munro, N. M., & de Lusignan, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0254-7 · Cited by 58
SGLT2 inhibitors and the kidney: Effects and mechanisms
Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. S. (2018) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.06.003 · Cited by 46
Bonora, B. M., Cappellari, R., Albiero, M., Avogaro, A., & Fadini, G. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00824 · Cited by 51
Sakai, T., & Miura, S. (2019) · Circulation Reports · doi:10.1253/circrep.cr-19-0018 · Cited by 55
Lim, S., Oh, T. J., Dawson, J., & Sattar, N. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 45
“It has also been suggested that SGLT2 inhibitors increase ketone levels, which may be related to protective effects on stroke prevention.(70) In rodent studies, β-hydroxybutyrate, one of the ketone bodies increased after SGLT2 inhibitor treatment, reduced brain infarct size through activating neuroprotective macrophag…”
BackgroundYu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01209-y · Cited by 50
Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
García‐Ropero, Á., Vargas-Delgado, A. P., Santos‐Gallego, C. G., & Badimón, J. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133289 · Cited by 49
Cardiovascular complications of diabetes
Shah, A., Isath, A. M., & Aronow, W. S. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099838 · Cited by 49
Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts
Birkenfeld, A. L., Jordan, J., Dworak, M., Merkel, T., & Burnstock, G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.015 · Cited by 50
“Moreover, treatment with SGLT-2 inhibitors also increases haematocrit and erythropoietin, possibly improving oxygen delivery to tissues and organs (Ferrannini et al., 2016; Ferrannini et al., 2017; Lambers Heerspink, de Zeeuw, Wie, Leslie, & List, 2013).”
BackgroundComparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes
Kramer, C. K., Ye, C., Campbell, S., & Retnakaran, R. R. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.021 · Cited by 48
SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
Muric, M. D., Zivkovic, V. I., Joksimović, J., Sretenovic, J. Z., Davidović, G., Simovic, S. M., Djoković, D., Muric, N. N., Bolevich, S., & Jakovljevic, V. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10079-9 · Cited by 49
Lim, S. K., Eckel, R. H., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.03.013 · Cited by 48
Lee, S. Y., Lee, T. W., Park, G. T., Kim, J. H., Lee, H.-C., Han, J.-H., Yoon, A., Yoon, D., Kim, S., Jung, S. M., et al. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2020.0303 · Cited by 45
Miranda‐Silva, D., Lima, T., Rodrigues, P., Leite-Moreira, A. F., & Falcão‐Pires, I. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10042-0 · Cited by 49
Sayour, A. A., Celeng, C., Oláh, A., Ruppert, M., Merkely, B. P., & Radovits, T. (2021) · Diabetologia · doi:10.1007/s00125-020-05359-2 · Cited by 47
Wang, X., Ni, J., Guo, R., Li, L., Su, J., He, F., & Fan, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10096-8 · Cited by 49
Werbner, B., Tavakoli‐Rouzbehani, O. M., Fatahian, A. N., & Boudina, S. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.42 · Cited by 53
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.